Related references
Note: Only part of the references are listed.Risks and Benefits of Bisphosphonate Therapies
Carlen Reyes et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Clinical Implications of Hip Flexion in the Measurement of Spinal Bone Mineral Density
Shota Ikegami et al.
JOURNAL OF CLINICAL DENSITOMETRY (2016)
Bisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic Patients
Mikio Kamimura et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
S. Ferrari et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
Yukio Nakamura et al.
BMC ENDOCRINE DISORDERS (2015)
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
Ove Torring
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2015)
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
C. Roux et al.
BONE (2014)
Bisphosphonates: The first 40 years
R. Graham G. Russell
BONE (2011)
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase
Verena Stresing et al.
BONE (2011)
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
A. Blumsohn et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
Jun Iwamoto et al.
CLINICAL INTERVENTIONS IN AGING (2008)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
